Literature DB >> 27270364

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.

Dan Călugăru1, Mihai Călugăru1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27270364     DOI: 10.1016/j.ajo.2016.05.015

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  7 in total

1.  Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-07       Impact factor: 3.117

2.  Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2016-11-04       Impact factor: 3.775

3.  Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-09       Impact factor: 3.117

4.  Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-20       Impact factor: 3.117

Review 5.  Bevacizumab in the treatment of acute central/hemicentral retinal vein occlusions.

Authors:  Dan Călugăru; Mihai Călugăru; Ștefan Țălu
Journal:  Rom J Ophthalmol       Date:  2016 Jul-Sep

6.  Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema.

Authors:  Sameh Mosaad Fouda; Ahmed M Bahgat
Journal:  Clin Ophthalmol       Date:  2017-03-23

7.  Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice.

Authors:  Beverley A Curry; Paul G Sanfilippo; Sarah Chan; Alexander W Hewitt; Nitin Verma
Journal:  Ophthalmol Ther       Date:  2019-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.